Researchers begin trial of nasal spray COVID-19 vaccine
KPWHRI is 1 of 6 sites testing the vaccine, which was developed by Boost Biopharma Inc.
Kaiser Permanente Washington Health Research Institute (KPWHRI) is taking part in a clinical trial of a nasal spray COVID-19 vaccine. The vaccine contains molecules called protein antigens, which produce an immune response by mimicking a part of the virus. Administering the vaccine as a nasal spray offers the potential to create an additional layer of protection, known as mucosal immunity.
“This may offer a way to both prevent COVID-19 infections in vaccinated persons as well as to block the onward transmission of COVID-19,” said Lisa Jackson, MD, the KPWHRI senior investigator who is overseeing the research at the institute.
The trial is taking place at 6 research sites across the United States. Half of the sites — including KPWHRI’s Seattle research clinic — will test the nasal vaccine. The other half will test a version of the vaccine delivered via an intramuscular injection.
For this Phase 1 trial, the researchers will evaluate whether the vaccines are safe and can help the body produce antibodies against the COVID-19 virus. The research is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
How to take part in the trial
Recruitment for this trial has now ended.
By Sophie Ramsey
Research
Using analytics to prevent adverse COVID-19 outcomes
Paper describes a novel predictive model that identifies patients at high risk of hospitalization or death.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.